RKLB · Rocket Lab

The thesis

Rocket Lab has a modestly better-than-even chance of beating the S&P 500 over the next three months. The reasons are record revenue, a $3.57 billion backlog and higher margin guidance. The case is settled by whether the company gives Neutron a dated launch quarter and books fourth-quarter revenue inside its $270–290 million guidance.

The company's 9 November 2026 release shows third-quarter revenue of a record $267.8 million, up 73% year over year. That beat the $250–265 million guidance. GAAP (generally accepted accounting principles) gross margin was 33.6%, against 29–31% guidance. Backlog rose 52% in one quarter to $3.57 billion at 30 September 2026.

The weak spot is Neutron, the company's medium-lift rocket. The release targets its first launch "no earlier than 2027" and gives no quarter. The shares fell after hours on 9 November 2026, then recovered during regular trading. They closed at $62.71 on 10 November 2026, $66.15 on 11 November 2026 and $64.07 on 12 November 2026, all above the $58.86 close before the report.

The price reflects the Neutron delay. At $64.07 on 12 November 2026, the shares sat 57.6% below the $151.00 intraday high of 27 May 2026 and under their 200-day moving average. Analysts cut their price targets after the report, and every revised target named in Benzinga's 10 November to 12 November 2026 coverage stays above that close.

Bullish and bearish views on Rocket Lab Corporation

The bull case on Rocket Lab Corporation (RKLB), in brief: revenue and margins beat guidance. The bear case: Neutron still has no launch quarter.

Bull case

• Revenue and margins beat guidance. Third-quarter revenue was $267.8 million against $250–265 million guidance. Non-GAAP gross margin was 38.4% against 35–37% guidance, according to the company's 9 November 2026 8-K.
• Backlog jumped 52% in one quarter. Backlog reached $3.57 billion at 30 September 2026. The release credits about $1 billion of new launch contracts and $470 million of new Space Systems contracts.
• Neutron already has paying customers. In the third quarter Rocket Lab signed eight Neutron missions worth more than $515 million with five constellation operators, including ICEYE. That took Neutron's backlog to 16 missions, according to the 9 November 2026 release.
• Guidance points higher again. Fourth-quarter revenue is guided to $270–290 million, above the $265.4 million estimate Benzinga cited on 9 November 2026. GAAP gross margin is guided to 34–36%. The adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation) loss is guided to $14–20 million.
• Targets fell but stay above the price. On 10 November 2026 and 11 November 2026, Benzinga reported targets of $111 at Cantor Fitzgerald, $103 at Morgan Stanley (cut from $105), $100 at Needham and $100 at KeyBanc, and $82 at Barclays. Berenberg raised its target to $85 from $83 on 12 November 2026. Cantor's note pointed to tight launch supply as Falcon 9 bookings fill up.
• Execution continues in both businesses. On 10 November 2026 Rocket Lab said both ESCAPADE spacecraft it built for NASA and the University of California, Berkeley had completed their trans-Mars injection burns. On 12 November 2026 it said the 100th Electron launch, carrying an iQPS radar satellite, is scheduled for no earlier than 14 November 2026.
• The balance sheet is large. The 8-K shows cash and cash equivalents of $4.45 billion at 30 September 2026, plus $256.2 million of marketable securities. On the 9 November 2026 call, management said the Iridium acquisition is fully financed.

Bear case

• Neutron still has no launch quarter. On the 9 November 2026 call, chief executive Peter Beck linked the slip to voids found in the forward dome of the propellant tank. He gave no quarter for first launch.
• Profitability waits on Neutron. On 9 November 2026, chief financial officer Adam Spice said adjusted EBITDA "will turn positive within six months of that first successful test flight". He said positive cash flow would come later. The third-quarter adjusted EBITDA loss was $18.0 million.
• Per-share losses missed estimates. Benzinga reported on 9 November 2026 a GAAP loss of $0.12 per share against a $0.06 estimate, and an adjusted loss of $0.08 against $0.07. The GAAP net loss was $79.7 million.
• The share count keeps rising. Common shares outstanding rose to 639.2 million at 30 September 2026 from 543.6 million at 31 December 2025. Management guided fourth-quarter basic weighted-average shares to about 681 million.
• Insiders sold into the October and November prices. SEC Form 4 filings show chief financial officer Adam Spice sold 140,157 shares on 1 October 2026 at an average of $70.82. He sold another 140,157 on 2 November 2026 at an average of $52.79. Director Nina Armagno sold 10,926 shares on 2 November 2026 at an average of $52.78. All of these sales were under Rule 10b5-1 trading plans.
• The Iridium deal faces competitor objections. Globalstar and SpaceX have raised concerns with the Federal Communications Commission (FCC). Rocket Lab and Iridium asked the FCC to expedite approval on 9 November 2026, according to Stocktwits.

Price setup

The shares closed at $64.07 on 12 November 2026, according to adjusted daily closes. That is above the 50-day moving average of $62.51 and below the 200-day moving average of $78.40. The three-month change is −20.2%, measured from an $80.25 close on 14 August 2026.

The rebound began from a $45.99 close on 5 November 2026. The shares then closed at $53.07 on 6 November 2026, $58.86 on 9 November 2026 and $62.71 on 10 November 2026. The $45.99 close is the low before the rebound. The 52-week closing low is $39.48, set on 20 November 2025.

Above the current price, the 200-day moving average is the first marker, followed by the $151.00 intraday high of 27 May 2026. A close back above the 200-day average would show the market looking past the Neutron delay. Benzinga reported Ark Invest buying Rocket Lab shares on 10 November 2026 and 11 November 2026.

Catalysts ahead

• ~25 February 2027 (est.): Fourth-quarter 2026 results. Shows whether revenue lands inside $270–290 million with a 34–36% GAAP gross margin. It is also the next scheduled point for the company to give Neutron a launch quarter.
• 28 June 2027: Outside date for the Iridium acquisition; FCC review pending. FCC approval would remove the main regulatory risk to the deal. An order blocking it, or a termination, would break the acquisition part of the case.

Elapsed catalysts

• 14 November 2026: 100th Electron launch, 'The Mountain God Rises', carrying an iQPS radar satellite; window opens no earlier than this date. A clean 100th flight keeps the Electron launch rate on track, and Electron revenue funds the business while Neutron is delayed. A failure would hit both near-term revenue and confidence in the company's execution. (passed)

What would change the view

A daily close below $45.99, the 5 November 2026 close before the rebound, which would erase the whole post-sell-off recovery. Fourth-quarter 2026 revenue below the $270 million guidance floor, or Neutron slipping into the second half of 2027, would also break the case.

The risks this note tracks, each with what would confirm it:

• Neutron slips further within 2027, delaying positive adjusted EBITDA and extending spending. Confirmed by: a company statement or 8-K placing first launch in the second half of 2027 or later, or no launch quarter given at the fourth-quarter report.
• Continued share issuance dilutes per-share gains from revenue growth. Confirmed by: new at-the-market sales or a fresh equity offering disclosed in a 10-Q, 8-K or 424B5 filing.
• FCC objections from Globalstar and SpaceX delay or block the Iridium acquisition. Confirmed by: an FCC order preventing completion, conditions on the licence transfer, or a termination filing.
• Fourth-quarter growth falls short of the raised guidance. Confirmed by: fourth-quarter 2026 revenue below $270 million or GAAP gross margin below 34%.
• Electron reliability falters at a high launch rate. Confirmed by: a launch failure or a grounding announced by Rocket Lab, including on the 100th mission scheduled for no earlier than 14 November 2026.
• Market-wide selling in speculative growth and space shares outweighs company results. Confirmed by: declines like 5 November 2026, with SpaceX and other space names falling alongside Rocket Lab on no company news.

What it trades with

Rocket Lab trades more with the listed space group and with speculative growth stocks than with large defence contractors. On 5 November 2026 it fell with SpaceX in a market-wide sell-off with no company news. On 10 November 2026, Benzinga reported it trading lower early in the session with AST SpaceMobile and IonQ. It then closed at $62.71.

The largest single-stock moves have come from company news: Neutron timing on 14 October 2026 and the 9 November 2026 results. Broad swings in high-multiple technology shares still tend to outweigh company results in the sessions around them.